Immunomedics, Inc. Release: Combination of 90Y-Epratuzumab and Veltuzumab is Active in Non-Hodgkin Lymphoma
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
VANCOUVER, British Columbia, June 11, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU),a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that epratuzumab labeled with the radioisotope, yttrium-90 (90Y), given in small doses in combination with veltuzumab is therapeutically active in patients with aggressive non-Hodgkin lymphoma (NHL). Results from this multicenter study were presented by Michael B. Tomblyn, MD, of H. Lee Moffitt Cancer Center in Tampa, FL.
Help employers find you! Check out all the jobs and post your resume.
VANCOUVER, British Columbia, June 11, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU),a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that epratuzumab labeled with the radioisotope, yttrium-90 (90Y), given in small doses in combination with veltuzumab is therapeutically active in patients with aggressive non-Hodgkin lymphoma (NHL). Results from this multicenter study were presented by Michael B. Tomblyn, MD, of H. Lee Moffitt Cancer Center in Tampa, FL.
Help employers find you! Check out all the jobs and post your resume.